Click here to close now.



Welcome!

News Feed Item

Nasal Drug Delivery - Advances in Drug Therapies, Systemic Delivery and Device Technologies (Conference, London)

DUBLIN, March 13, 2014 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/jdzmv4/nasal_drug) have announced the addition of the "Nasal Drug Delivery - Advances in Drug Therapies, Systemic Delivery and Device Technologies (Conference, London)" conference to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

The Nasal Drug Delivery Conference will take place on the 3rd & 4th April 2014 at the Rembrandt Hotel, London

THREE REASONS TO ATTEND THIS EVENT

- Gain an update on the very latest scientific developments and technology advances in this field.

- Hear from an unrivaled panel of expert speakers.

- An excellent networking opportunity to build business relationships.

WHO SHOULD ATTEND

Managing Directors, Medical Directors, Head of Regulatory Affairs and Quality Assurance, Senior Executives in Research and Development, Registration, Marketing and all departments that may be involved in Nasal Drug Delivery, or who wish to understand the potential of this alternative therapeutic route. Those already involved in Nasal Drug Delivery will benefit from updating their knowledge and sharing experiences with some of the leading practitioners in this field. If you are involved in Nasal Drug Delivery or are just considering the potential, this conference is an excellent route to understanding all aspects from the basic physiology through to launching a successful product. 

CHAIRPERSON: Dr Rene Bommer

KEYNOTE SPEAKER: Prof. Michael S Benninger

DATES:

3 & 4 April 2014

TIMES:

3 April 2014: Start 09.30 - Finish 17.30
Drinks Reception: Start 17.30 - Finish 18.30
4 April 2014: Start 09.15 - Finish 16.30

REGISTRATION & COFFEE

3 April 2014 09.00

VENUE & ACCOMMODATION

The Rembrandt Hotel, 11 Thurloe Place, London SW7 2RS

DIRECTIONS:

Opposite V&A Museum. Nearest underground station: South Kensington.

NOTE: Events may be cancelled due to commercial or organisational reasons. In this case Research and Markets will refund all registration fees which have already been paid. Research and Markets will not refund any charges arising from the participant having to cancel or re-book transportation or accommodation which he or she has arranged 

Key Topics Covered: 

DAY ONE - 3 April 2014

09.30 u Chairman's Welcome and Introduction
Dr René Bommer, Director, pharmAccel Consulting, Germany 

Session 1: Advances in Drug Therapies: State of the Art

09.45 u Nasal Drugs to Treat Nasal Disorders; A Comprehensive Review

- Anatomy and physiology
- Nasal disorders
- Treatment options and future prospects to treat allergic and non-allergic Rhinitis
- Rhinosinusitis and Polyps

Professor Michael S. Benninger, Chairman, The Head and Neck Institute, Professor of Surgery, Lerner College of Medicine, The Cleveland Clinic, USA 

10.45 - Discussion 

11.00 - Coffee

Session 2: Progress in Local and Systemic Nasal Drug Delivery

11.30 - Particulate Systems for Nasal (Vaccine) Delivery

- Literature review on particulate systems for nasal delivery
- Nanoparticulate systems for direct uptake
- Particle requirements for nasal deposition
- Modification of particle surface/particle engineering
- Formulation design
- Implications in nasal vaccine development

Dr Regina Scherliess, Christian Albrecht University of Kiel, Department of Pharmaceutics and Biopharmaceutics, Germany

12.10 - Antiviral Polymers - A Novel Concept of Intranasal Therapy Against Respiratory Viruses

- Marinomed has developed a technology for creating a protective physical barrier in the nasal cavity with antiviral polymers for the prevention and therapy of common cold and influenza

- Independent clinical trials in adults and children demonstrated that the intranasal administration of Iota-Carrageenan significantly reduced the time to disease clearance of patients with common cold and decreased the virus load in nasal lavages

- The existing product portfolio will be expanded and the new developments focus on combination products for the treatment of influenza and the prevention of virally-induced exacerbations in allergic patients 

Dr Angelika Bodenteich, Head of Development, Marinomed Biotechnologie, GmbH, Germany

12.50 - Discussion

13.00 - Lunch

14.00 - Nasal Drug Delivery - The Technology Whose Potential Has Not Yet Been Valorised

- Current technologies for nasal drug delivery
- Nasal application for unmet medical needs
- Factors affecting bioavailability and response after nasal application
- Symbiosis of formulation and device
- Identification of potential obstacles in product development

Dr Claudia Mattern, Adjunct Professor Nova Southeastern University, US-FL, Chief Scientific Officer, M & P Pharma AG, Switzerland 

Session 3: Nasal Devices, Device Testing and New Technologies

14.40 - Review of Nasal Drug Delivery Devices

- Business aspects
- Device technologies and nasal delivery systems
- Regulatory aspects
- Nasl spray characterisation 

Dr René Bommer, Director, pharmAccel Consulting, Germany 

15.20 - Discussion 

15.30 - Tea

16.00 - New Trends in Nasal Delivery with Dry Powder Formulations

- Dry powder formulations represent attractive alternatives to liquid formulations

- Systemic delivery via the nasal cavity, including pain treatments and also intra-nasal vaccination, are being investigated and developed with dry powder formulation because it offers a number of benefits like thermal and microbiologic stability and the variability of the physico-chemical properties

- Regulatory Aptar pharma offers a line of disposable primeless devices designed specifically for liquid and for dry powder formulations

- Opportunities and case studies using our Unit Dose Powder, Single Dose Device technology platform

Holger Kehrer, Business Support Manager, Aptar pharma, France 

16.40 - Update on Advancia: Innovative Design Solution to Respond to New Challenges in Nasal Delivery

- Recent trends in nasal spray delivery
- Compliance, efficiency, convenience and ease of use of nasal delivery devices
- Regulatory requirement changes for nasal delivery requiring next generation devices

Pascale Farjas, Global Category Manager, Rexam Healthcare, France 

17.20 - Discussion 

17.30 - Close of Day One

17.30 - 18.30 Drinks Reception for Delegates and Speakers

DAY TWO - 4 April 2014

09.15 - Chairman's Review of Day One 

Dr René Bommer, Director, pharmAccel Consulting, Germany 

Session 4: Nasal Devices, Device Testing and New Technologies (continued)

09.30 - Current Nasal Powder Technologies: The Challenge of Powder Dosing

- Dosing requirements (dosing range, target to be filled, powder properties)
- Overview dosing systems (design, functionality)
- Examples of filling equipment (developmental equipment)
- Systems for fill weight verification (IPC, PAT,..)

Marco Laackmann, Division Leader, Inhalation, Harro Höfliger, Germany 

10.10 - Addressing Technical Barriers in Nasal Dry Powder Delivery 

- Patient / user needs - clinical trials, comfort, understanding
- Device requirements - materials, regulatory, risks
- Formulation requirements - dosage, residence time, stability
- Product performance - deposition, particle size distribution, plume geometry, shelf life
- Commercialisation - competition, cost, IP, market need, regulatory acceptance, USP

Ian Harrison, Chief Scientific Officer, Alchemy Pharmatech, UK 

10.50 - Discussion

11.00 - Coffee

11.30 - How Technology Can be Used to Enhance our Understanding of User Behaviour and Influence the Way we Conduct User Research

- Social Intelligence for greater product understanding
- Gaining access to the right study participants
- Field research from your desk
- Quantifying human performance
- Seeing through our users eyes
- Understanding emotional responses and states of mind

Miranda Newberry, Human Factors Consultant, PA Consulting, UK

12.10 - A Platform Approach to Developing Patient Oriented Drug Delivery Systems and Products

- This approach to the development of drug delivery technology solutions is unconventional, risky and offers tremendous potential for developing drug/device combination products that deliver unparalleled value to both the patient and the manufacturer

- This well-executed platform based approach seeks to reduce the complexity of developing new combination products without sacrificing innovation

- Progress of Mystic's drug delivery platform solutions, its capabilities, applications and the benefits for patients and Pharma/biotech manufacturers
Timothy Sullivan, President & CEO, Mystic Pharmaceuticals Inc., USA (invited)

12.50 - Discussion

13.00 - Lunch

Session 5: Regulatory Requirements

14.00 - EU Regulatory Requirements 

- Differences between pulmonary and nasal requirements
- Bio-equivalence Representative from a Regulatory Agency, (invited)

14.40 - Discussion

Session 6: Business and Intellectual Property (IP) in Nasal Systemic Drug Delivery

14.50 - Choosing the Best Way to Finance Your Company 

- First: get the business model right
- Starting out - is there easy money?
- Angels vs Dragons
- Dilutive vs non-dilutive financing
- Financing through partnering
- Planning an exit - IPO vs Trade Sale

Finton Walton, CEO, Pharma Ventures, UK

15.30 - R&D Collaborations for Drug Delivery: Legal and Contractual Issues

- The different priorities of universities, start-ups and major companies
- Benefits of term sheets / letters of intent and how to use them
- Defining the scope of the collaboration: work, field, etc.
- IP ownership and licences
- Other legal issues

Mark Anderson, Solicitor, Anderson Law LLP, UK

16.10 u Discussion

16.20 u Chairman's Concluding Remarks

16.30 u Close of Conference and Tea 

For more information visit http://www.researchandmarkets.com/research/jdzmv4/nasal_drug

Media Contact: Laura Wood, +353-1-481-1716, [email protected]

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Advances in technology and ubiquitous connectivity have made the utilization of a dispersed workforce more common. Whether that remote team is located across the street or country, management styles/ approaches will have to be adjusted to accommodate this new dynamic. In his session at 17th Cloud Expo, Sagi Brody, Chief Technology Officer at Webair Internet Development Inc., focused on the challenges of managing remote teams, providing real-world examples that demonstrate what works and what do...
As enterprises work to take advantage of Big Data technologies, they frequently become distracted by product-level decisions. In most new Big Data builds this approach is completely counter-productive: it presupposes tools that may not be a fit for development teams, forces IT to take on the burden of evaluating and maintaining unfamiliar technology, and represents a major up-front expense. In his session at @BigDataExpo at @ThingsExpo, Andrew Warfield, CTO and Co-Founder of Coho Data, will dis...
SYS-CON Events announced today that Fusion, a leading provider of cloud services, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Fusion, a leading provider of integrated cloud solutions to small, medium and large businesses, is the industry's single source for the cloud. Fusion's advanced, proprietary cloud service platform enables the integration of leading edge solutions in the cloud, including clou...
As someone who has been dedicated to automation and Application Release Automation (ARA) technology for almost six years now, one of the most common questions I get asked regards Platform-as-a-Service (PaaS). Specifically, people want to know whether release automation is still needed when a PaaS is in place, and why. Isn't that what a PaaS provides? A solution to the deployment and runtime challenges of an application? Why would anyone using a PaaS then need an automation engine with workflow ...
With the Apple Watch making its way onto wrists all over the world, it’s only a matter of time before it becomes a staple in the workplace. In fact, Forrester reported that 68 percent of technology and business decision-makers characterize wearables as a top priority for 2015. Recognizing their business value early on, FinancialForce.com was the first to bring ERP to wearables, helping streamline communication across front and back office functions. In his session at @ThingsExpo, Kevin Roberts...
SYS-CON Events announced today that Commvault, a global leader in enterprise data protection and information management, has been named “Bronze Sponsor” of SYS-CON's 18th International Cloud Expo, which will take place on June 7–9, 2016, at the Javits Center in New York City, NY, and the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Commvault is a leading provider of data protection and information management...
Your business relies on your applications and your employees to stay in business. Whether you develop apps or manage business critical apps that help fuel your business, what happens when users experience sluggish performance? You and all technical teams across the organization – application, network, operations, among others, as well as, those outside the organization, like ISPs and third-party providers – are called in to solve the problem.
SYS-CON Events announced today that Alert Logic, Inc., the leading provider of Security-as-a-Service solutions for the cloud, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Alert Logic, Inc., provides Security-as-a-Service for on-premises, cloud, and hybrid infrastructures, delivering deep security insight and continuous protection for customers at a lower cost than traditional security solutions. Ful...
@DevOpsSummit taking place June 7-9, 2016 at Javits Center, New York City, and Nov 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with the 18th International @CloudExpo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. @DevOpsSummit at Cloud Expo New York Call for Papers is now open.
SYS-CON Events announced today that VAI, a leading ERP software provider, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. VAI (Vormittag Associates, Inc.) is a leading independent mid-market ERP software developer renowned for its flexible solutions and ability to automate critical business functions for the distribution, manufacturing, specialty retail and service sectors. An IBM Premier Business Part...
Let’s face it, embracing new storage technologies, capabilities and upgrading to new hardware often adds complexity and increases costs. In his session at 18th Cloud Expo, Seth Oxenhorn, Vice President of Business Development & Alliances at FalconStor, will discuss how a truly heterogeneous software-defined storage approach can add value to legacy platforms and heterogeneous environments. The result reduces complexity, significantly lowers cost, and provides IT organizations with improved effi...
SYS-CON Events announced today that Catchpoint Systems, Inc., a provider of innovative web and infrastructure monitoring solutions, has been named “Silver Sponsor” of SYS-CON's DevOps Summit at 18th Cloud Expo New York, which will take place June 7-9, 2016, at the Javits Center in New York City, NY. Catchpoint is a leading Digital Performance Analytics company that provides unparalleled insight into customer-critical services to help consistently deliver an amazing customer experience. Designed...
SYS-CON Events announced today that Pythian, a global IT services company specializing in helping companies adopt disruptive technologies to optimize revenue-generating systems, has been named “Bronze Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2015 at the Javits Center in New York, New York. Founded in 1997, Pythian is a global IT services company that helps companies compete by adopting disruptive technologies such as cloud, Big Data, advanced analytics, and DevO...
SYS-CON Events announced today that Men & Mice, the leading global provider of DNS, DHCP and IP address management overlay solutions, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. The Men & Mice Suite overlay solution is already known for its powerful application in heterogeneous operating environments, enabling enterprises to scale without fuss. Building on a solid range of diverse platform support,...
With an estimated 50 billion devices connected to the Internet by 2020, several industries will begin to expand their capabilities for retaining end point data at the edge to better utilize the range of data types and sheer volume of M2M data generated by the Internet of Things. In his session at @ThingsExpo, Don DeLoach, CEO and President of Infobright, will discuss the infrastructures businesses will need to implement to handle this explosion of data by providing specific use cases for filte...